Data First: Enhancing Drug Development with FAIR-by-Design Standards
Discover how FAIR-by-design standards can revolutionize data management in new approach methodologies for drug development.
- Publisher
- neuronautix.com
- Length
- 14 pages
- File
- 0 B PDF
Why this matters
FAIR-by-design standardization is a necessary investment for maximizing NAM data utility.
Executive summary
- FAIR-by-design standardization is a necessary investment for maximizing NAM data utility.
- Existing infrastructure like NAMO can facilitate data interoperability and reusability.
- Regulatory bodies are increasingly requiring structured data for NAM acceptance.
AI research brief
Discover how FAIR-by-design standards can revolutionize data management in new approach methodologies for drug development.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Who should read this
- Regulatory affairs teams
Ask about this report
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Download the full 14-page PDF
Free · 0 B · Instant access after email
FAIR-by-design standardization is a necessary investment for maximizing New Approach Methodology (NAM) data utility, enabling significant cost savings, improved data integration, and faster regulatory submissions.
Key Takeaways
- FAIR-by-design standardization is a necessary investment for maximizing NAM data utility.
- Existing infrastructure like NAMO can facilitate data interoperability and reusability.
- Regulatory bodies are increasingly requiring structured data for NAM acceptance.
What challenges do NAMs face?
NAMs face challenges due to incompatible data formats, hindering data reuse and aggregation. This whitepaper from neuronautix.com advocates for FAIR-by-design standards to enhance data management and regulatory acceptance.
Why is FAIR-by-design important for pharma teams?
Adopting FAIR-by-design standards can lead to significant cost savings, improved data integration, and faster regulatory submissions, ultimately enhancing drug development efficiency.
Frequently Asked Questions
What is the New Approach Methodology Ontology and Schema (NAMO)?
NAMO, maintained by the Monarch Initiative, gives NAM data a shared vocabulary and schema that makes it Findable, Accessible, Interoperable, and Reusable by construction.
What is the FDA's stance on NAM data?
The FDA's March 2026 draft guidance on NAMs makes structured, context-of-use-aware data a precondition for acceptance.
What benefits can be expected from FAIR-by-design standardization?
FAIR-by-design standardization is a bounded upfront investment that pays compounding returns.
Related coverage
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
Related intelligence
Did You Know: Insights from NCPDP's Active Task Groups
NCPDP has 71 active task groups focusing on diverse areas of pharmacy standards.
A26 Informational Reports: Insights for Pharma Stakeholders
Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
★ FDA Seeks Input on Drug Repurposing for Unmet Medical Needs
FDA is establishing a public docket for drug repurposing input.